0001213900-17-011517.txt : 20171107 0001213900-17-011517.hdr.sgml : 20171107 20171107165429 ACCESSION NUMBER: 0001213900-17-011517 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171107 DATE AS OF CHANGE: 20171107 EFFECTIVENESS DATE: 20171107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-298256 FILM NUMBER: 171184109 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 D 1 primary_doc.xml X0708 D LIVE 0001711786 Hoth Therapeutics, Inc. 1 ROCKEFELLER PLAZA, SUITE 1039 NEW YORK NY NEW YORK 10020 646-756-2997 NEVADA None None Corporation true 2017 Robb Knie 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Executive Officer Director Promoter President and Chief Executive Officer Vadim Mats 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Kenneth Rice 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Anthony Hayes 1 Rockefeller Plaza, Suite 1039 New York NY NEW YORK 10020 Director Pharmaceuticals Decline to Disclose 06b false 2017-10-25 false true true true convertible preferred stock and warrants to purchase common stock false 10000 Laidlaw & Company (UK) Ltd. 119037 None None 546 FIFTH AVENUE, 5TH FLOOR NEW YORK NY NEW YORK 10005 CO COLORADO ID IDAHO NJ NEW JERSEY WI WISCONSIN true 5000000 1000000 4000000 false 5 650000 true 0 Laidlaw & Company (UK) Ltd. will receive a one-time activation fee of $50,000 and a cash commission and a non-accountable expense equal to 10% and 2%, respectively, of the aggregate gross proceeds. 150000 true To be used for payment of salary and board member fees. false Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie President and CEO 2017-11-07